Recent News

• 03.16.2026 - vTv Therapeutics to Participate in the 38th Annual ROTH Conference
• 03.10.2026 - vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
• 02.13.2026 - vTv Therapeutics to Participate in Upcoming Investor Conferences
• 02.02.2026 - vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
• 12.18.2025 - vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
• 11.06.2025 - vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 03.10.2026 - EX-99.1 EX-99.1
• 03.10.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2026 - 8-K Current report
• 03.10.2026 - 8-K Current report
• 03.10.2026 - EX-99.1 EX-99.1
• 02.26.2026 - EX-99.1 EX-99.1
• 02.26.2026 - 8-K Current report
• 02.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 8-K Current report